Commercial growth and reaffirmed guidance support execution, while Alzheimer's psychosis data is the major near-term catalyst.
| Quarter | Q1 FY26 |
|---|---|
| Length | 63 minutes |
| EPS | $0.02 |
| EPS consensus | $0.04 |
| Revenue | $268.1M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q4 FY25
All ACAD earnings · Back to ACAD overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.